Total Q1 revenue of $8.06 million increased 124% over the comparable
prior year period and 34% sequentially over Q4 2021
Accelerated Business-to-Business (B2B)
transformation with 14 new B2B accounts in Q1 2022, including two
health plans
Expanded GAAP gross margin to 49.4% and
non-GAAP gross margin to 61%
Improved overall financial profile with
increasing B2B revenue and reduced operating costs as B2B business
matures resulting in a lower net loss compared to Q4 2021
Company to host conference call and webcast
8:30 am ET today
NEW
YORK, May 12, 2022 /PRNewswire/
-- DarioHealth Corp. (Nasdaq: DRIO), a leader in the global
digital therapeutics (DTx) market, today reported financial results
for the first quarter 2022 and provided a corporate and commercial
update.
"Our first quarter results reflect our increasingly successful
transition to a B2B model with growing revenue and gross margins,"
stated Erez Raphael, Chief Executive
Officer of Dario. "We increased revenue nearly 124% over the first
quarter of last year and nearly 34% sequentially, and we expanded
our gross margin on a GAAP basis to 49.4% and on a non-GAAP basis
to 61%. Additionally, in light of the demonstrable traction and
increasing revenue in the B2B (commercial) market segment, we
continued to rationalize marketing spend in the direct-to-consumer
segment resulting in improved margins which drove a significantly
narrower net loss and cash burn rate as compared to the fourth
quarter of 2021.With the strategic agreement executed with Sanofi
U.S. (Sanofi) and the $40 million
financing that we closed in the quarter, we believe that we are in
an excellent position to achieve our financial and operational
goals for the foreseeable future," Mr. Raphael concluded.
"In addition to the innovative, multi-year collaboration that we
announced with Sanofi, we had a very productive quarter, adding 14
new B2B contracts, including two additional health plans, which we
expect will contribute revenues in the back half of this year,"
stated Rick Anderson, President and
General Manager of North America.
"We continue to see increasing interest and demand for our
integrated, multi-chronic condition platform, which continues to
grow, and we anticipate announcing many more customer conversions
from our growing pipeline over the remainder of the year."
Q1 2022 and Recent Highlights
- Generated total revenue of $8.06
million, representing an increase of 124% from the first
quarter of 2021, and 34% from the fourth quarter of 2021.
- Added 14 new accounts across the employer, health plan and
provider channels during Q1, reflecting continued momentum of B2B
segment.
- Signed a multi-year, multi-faceted $30
million agreement with Sanofi to accelerate adoption of
Dario's solution within the payer channel through joint sales
efforts and drive innovation through shared research initiatives
and development of new products for use on Dario's platform.
- Expanded GAAP gross margins to 49.4% and non-GAAP gross margins
to 61%.
- Raised $40 million through a
registered direct offering priced at the market.
- Announced acquisition of Physimax, a leading provider of
validated computer vision for musculoskeletal health.
- Presented new clinical research demonstrating improved outcomes
for participants using a single integrated digital solution to
manage multiple chronic conditions at the Advanced Technologies and
Treatments for Diabetes (ATTD) Conference, held April 27th – 30th.
First Quarter 2022 Results Summary
Revenues for the first quarter ended March 31, 2022, were $8.06
million, a 34% sequential increase from fourth quarter ended
December 31, 2021, and a 124%
increase from the $3.6 million in the
first quarter ended March 31, 2021.
The increase in revenues resulted from increased revenues in our
B2B commercial market segment.
Gross profit in the first quarter of 2022 was $4.0 million, an increase of $2.9 million, compared to gross profit of
$1.1 million in the first quarter of
2021. Gross profit as a percentage of revenues increased from 30.1%
in the first quarter of 2021 to 49.4% in the first quarter of
2022.
Pro-forma gross profit, excluding $932,000 of non-cash amortization of expenses
related to the acquisition of technology, was $4.9 million, or 61% of revenues, for the three
months ended March 31, 2022.
Total operating expenses for the first quarter of 2022 were
$19.9 million compared with
$15.4 million for the first quarter
of 2021 and $22.2 million in the
fourth quarter of 2021, an increase of $4.5
million, or 28.9%, compared to the first quarter of 2021,
and a decrease of $2.3 million, or
10.6%, compared to the fourth quarter of 2021. The increase
compared to the first quarter of 2021 resulted from an increase in
our operating expenses. The decrease compared to the fourth quarter
of 2021 resulted from a decrease in our direct to consumer
marketing expenses. Total operating expenses excluding stock-based
compensation, acquisition expenses and depreciation for the first
quarter of 2022 were $14.8 million
compared to $10.6 million for the
first quarter of 2021, and $16.4
million in the fourth quarter of 2021.
Operating loss for the first quarter of 2022 was $15.9 million, an increase of $1.55 million, or 10.8%, compared to the
$14.3 million operating loss in the
first quarter of 2021, and a decrease of $5.8 million or 26.7% compared to the
$21.7 million operating loss in the
fourth quarter of 2021. The increase compared to the first quarter
of 2021 was mainly due to the increase in our operating expenses,
and the decrease compared to the fourth quarter of 2021 was mainly
due to the increase in the gross profit and the decrease in
operating expenses.
Net loss was $15.9 million in the
first quarter of 2022, an increase of $0.9
million, or 6.3%, compared to the $15
million net loss in the first quarter of 2021, and a
decrease of $5.7 million, or 26.3%
compared to the fourth quarter of 2021. Net loss excluding
stock-based compensation, acquisition expenses and depreciation for
the first quarter of 2022 was $9.9
million compared to $9.6
million for the first quarter of 2021 and $14.9 million in the fourth quarter of 2021.
Non-GAAP billings for the three months ended March 31, 2022, were $7.96
million, a 116% increase from $3.69
million reported for the three months ended March 31, 2021. The increase is a result of
higher sales generated in the three months ended March 31, 2022, compared to the three months
ended March 31, 2021. A
reconciliation of GAAP to non-GAAP measures has been provided in
the financial statement tables included in this press release. An
explanation of these measures is also included below under the
heading "Non-GAAP Financial Measures."
Conference Call Details: Thursday, May
12, 8:30am ET
Dial-in Number: 844-826-3035
International Dial-in: 412-317-5195
Conference ID: DarioHealth First Quarter 2022 Results
Call
Webcast:
https://viavid.webcasts.com/starthere.jsp?ei=1547229&tp_key=ae83ab1839
Participants are asked to dial-in approximately 10 minutes prior
to the start of the event. A replay of the call will be available
approximately two hours after completion through June 12, 2022. To listen to the replay, dial
844-512-2921 (domestic) or 412-317-6671 (international) and use
replay passcode 10166824.
About DarioHealth Corp.
DarioHealth Corp. (Nasdaq: DRIO) is a leading global digital
therapeutics company revolutionizing how people with chronic
conditions manage their health. DarioHealth offers one of the most
comprehensive digital therapeutics solutions on the market -
covering multiple chronic conditions including diabetes,
hypertension, weight management, musculoskeletal and behavioral
health within one integrated technology platform.
Dario's next-generation, AI-powered, digital therapeutic
platform supports more than just an individual's disease. Dario
provides adaptive, personalized experiences that drive behavior
change through evidence-based interventions, intuitive, clinically
proven digital tools, high-quality software, and coaching to help
individuals improve health and sustain meaningful outcomes.
Dario's unique user-centric approach to product design and
engagement creates an unparalleled experience that is highly rated
by users and delivers sustainable results.
The company's cross-functional team operates at the intersection
of life sciences, behavioral science, and software technology and
utilizes a performance-based approach to improve its users'
health.
On the path to better health, Dario makes the right thing to do
the easy thing to do. To learn more about DarioHealth and its
digital health solutions or for more information, visit
http://dariohealth.com.
Cautionary Note Regarding Forward-Looking Statements
This news release and the statements of representatives and
partners of DarioHealth Corp. (the "Company") related thereto
contain or may contain forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
Statements that are not statements of historical fact may be deemed
to be forward-looking statements. Without limiting the generality
of the foregoing, words such as "plan," "project," "potential,"
"seek," "may," "will," "expect," "believe," "anticipate," "intend,"
"could," "estimate" or "continue" are intended to identify
forward-looking statements. For example, the Company is using
forward-looking statements in this press release when it discusses
that its first quarter results reflect its increasingly successful
transition to a B2B model with growing revenue and gross margins,
the belief that it is in an excellent position to achieve its
financial and operational goals for the foreseeable future, the
expected timing of the contribution of revenues from its new B2B
contracts, the interest and demand seen for its platform and its
anticipation of announcing many more customer conversions from its
growing pipeline over the remainder of the year. Readers are
cautioned that certain important factors may affect the Company's
actual results and could cause such results to differ materially
from any forward-looking statements that may be made in this news
release. Factors that may affect the Company's results include, but
are not limited to, regulatory approvals, product demand, market
acceptance, impact of competitive products and prices, product
development, commercialization or technological difficulties, the
success or failure of negotiations and trade, legal, social and
economic risks, and the risks associated with the adequacy of
existing cash resources. Additional factors that could cause or
contribute to differences between the Company's actual results and
forward-looking statements include, but are not limited to, those
risks discussed in the Company's filings with the U.S. Securities
and Exchange Commission. Readers are cautioned that actual results
(including, without limitation, the timing for and results of the
Company's commercial and regulatory plans for Dario™ as described
herein) may differ significantly from those set forth in the
forward-looking statements. The Company undertakes no obligation to
publicly update any forward-looking statements, whether as a result
of new information, future events or otherwise, except as required
by applicable law.
Non-GAAP Financial Measures
We have provided in this release financial information that has
not been prepared in accordance with Generally Accepted Accounting
Principles (GAAP). These non-GAAP financial measures are not based
on any standardized methodology prescribed by GAAP and are not
necessarily comparable to similar measures presented by other
companies. We use these non-GAAP financial measures internally in
analyzing our financial results and believe they are useful to
investors, as a supplement to GAAP measures, in evaluating our
ongoing operational performance. We believe that the use of these
non-GAAP financial measures provides an additional tool for
investors to use in evaluating ongoing operating results and trends
and in comparing our financial results with peer companies, many of
which present similar non-GAAP financial measures to investors.
Non-GAAP financial measures should not be considered in
isolation from, or as a substitute for, financial information
prepared in accordance with GAAP. Investors are encouraged to
review the reconciliation of these non-GAAP financial measures to
their most directly comparable GAAP financial measures provided in
the financial statement tables below.
Billings (non-GAAP). We define billings as revenue
recognized in accordance with GAAP plus the change in deferred
revenue from the beginning to the end of the period and adjustment
to the deferred revenue balance due to adoption of the new revenue
recognition standard less any deferred revenue balances acquired
from business combination(s) during the period. We consider
billings to be a useful metric for management and investors because
billings drive future revenue, which is an important indicator of
the health and viability of our business. There are a number of
limitations related to the use of billings instead of GAAP revenue.
First, billings include amounts that have not yet been recognized
as revenue and are impacted by the term of security and support
agreements. Second, we may calculate billings in a manner that is
different from peer companies that report similar financial
measures. Management accounts for these limitations by providing
specific information regarding GAAP revenue and evaluating billings
together with GAAP revenue.
Operating expenses (non-GAAP). Our presentation of
non-GAAP operating expenses excludes stock-based compensation
expenses. Due to varying available valuation methodologies,
subjective assumptions, and the variety of equity instruments that
can impact a company's non-cash operating expenses, we believe that
providing non-GAAP financial measures that exclude non-cash expense
provides us with an important tool for financial and operational
decision making and for evaluating our own core business operating
results over different periods of time.
Net loss (non-GAAP). Our presentation of adjusted net
loss excludes the effect of certain items that are non-GAAP
financial measures. Adjusted net loss represents net loss
determined under GAAP without regard to stock-based compensation
expenses, deferred inventory and depreciation of fixed assets. We
believe these measures provide useful information to management and
investors for analysis of our operating results.
DARIOHEALTH CORP.
AND ITS SUBSIDIARIES
|
|
INTERIM CONSOLIDATED
BALANCE SHEETS
|
|
U.S. dollars in
thousands
|
|
|
|
|
|
March 31,
|
|
December 31,
|
|
|
|
2022
|
|
2021
|
|
|
|
Unaudited
|
|
|
|
|
ASSETS
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CURRENT
ASSETS:
|
|
|
|
|
|
|
|
Cash and
cash equivalents
|
|
$
|
55,558
|
|
$
|
35,808
|
|
Short-term restricted bank deposits
|
|
|
190
|
|
|
192
|
|
Trade
receivables
|
|
|
4,574
|
|
|
1,310
|
|
Inventories
|
|
|
7,783
|
|
|
6,228
|
|
Other
accounts receivable and prepaid expenses
|
|
|
3,271
|
|
|
2,067
|
|
|
|
|
|
|
|
|
|
Total current
assets
|
|
|
71,376
|
|
|
45,605
|
|
|
|
|
|
|
|
|
|
NON-CURRENT
ASSETS:
|
|
|
|
|
|
|
|
Deposits
|
|
|
7
|
|
|
20
|
|
Operating
lease right of use assets
|
|
|
280
|
|
|
287
|
|
Long-term
assets
|
|
|
16
|
|
|
57
|
|
Property
and equipment, net
|
|
|
698
|
|
|
702
|
|
Intangible assets, net
|
|
|
13,314
|
|
|
12,460
|
|
Goodwill
|
|
|
41,640
|
|
|
41,640
|
|
|
|
|
|
|
|
|
|
Total non-current
assets
|
|
|
55,955
|
|
|
55,166
|
|
|
|
|
|
|
|
|
|
Total assets
|
|
$
|
127,331
|
|
$
|
100,771
|
|
|
|
|
|
|
|
|
|
|
DARIOHEALTH CORP.
AND ITS SUBSIDIARIES
|
INTERIM CONSOLIDATED
BALANCE SHEETS
|
U.S. dollars in
thousands (except stock and stock data)
|
|
|
|
March 31,
|
|
December 31,
|
|
|
|
2022
|
|
2021
|
|
|
|
Unaudited
|
|
|
|
|
LIABILITIES AND STOCKHOLDERS' EQUITY
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CURRENT
LIABILITIES:
|
|
|
|
|
|
|
|
Trade
payables
|
|
$
|
4,228
|
|
$
|
5,109
|
|
Deferred
revenues
|
|
|
1,093
|
|
|
1,195
|
|
Operating
lease liabilities
|
|
|
212
|
|
|
266
|
|
Other
accounts payable and accrued expenses
|
|
|
7,192
|
|
|
7,806
|
|
Earn out
liability
|
|
|
373
|
|
|
825
|
|
|
|
|
|
|
|
|
|
Total current
liabilities
|
|
|
13,098
|
|
|
15,201
|
|
|
|
|
|
|
|
|
|
NON-CURRENT
LIABILITIES
|
|
|
|
|
|
|
|
Operating
lease liabilities
|
|
|
48
|
|
|
21
|
|
|
|
|
|
|
|
|
|
Total non-current
liabilities
|
|
|
48
|
|
|
21
|
|
|
|
|
|
|
|
|
|
STOCKHOLDERS'
EQUITY
|
|
|
|
|
|
|
|
Common
stock of $0.0001 par value - Authorized: 160,000,000 shares at
March 31, 2022 (unaudited) and December 31, 2021;
Issued and
Outstanding: 22,070,963 and 16,573,420 shares at
March 31, 2022
(unaudited) and December 31, 2021,
respectively
|
|
|
2
|
|
|
2
|
|
Preferred
stock of $0.0001 par value - Authorized: 5,000,000 shares at
March 31, 2022 (unaudited) and December 31, 2021;
Issued and
Outstanding: 10,897 and 11,927 shares at March 31,
2022 (unaudited)
and December 31, 2021, respectively
|
|
|
*) -
|
|
|
*) -
|
|
Additional paid-in capital
|
|
|
352,564
|
|
|
307,561
|
|
Accumulated deficit
|
|
|
(238,381)
|
|
|
(222,014)
|
|
|
|
|
|
|
|
|
|
Total stockholders'
equity
|
|
|
114,185
|
|
|
85,549
|
|
|
|
|
|
|
|
|
|
Total liabilities and
stockholders' equity
|
|
$
|
127,331
|
|
$
|
100,771
|
|
DARIOHEALTH CORP.
AND ITS SUBSIDIARIES
|
INTERIM CONSOLIDATED
STATEMENTS OF COMPREHENSIVE LOSS
|
U.S. dollars in
thousands (except stock and stock data)
|
|
|
|
Three months
ended
|
|
|
|
March 31,
|
|
|
|
2022
|
|
2021
|
|
|
|
Unaudited
|
|
Revenues
|
|
$
|
8,059
|
|
$
|
3,595
|
|
Cost of revenues
(excluding of amortization and inventories step-up
shown separately below)
|
|
|
3,142
|
|
|
1,988
|
|
Amortization of
acquired intangible assets and inventories step-up
|
|
|
932
|
|
|
526
|
|
|
|
|
|
|
|
|
|
Gross profit
|
|
|
3,985
|
|
|
1,081
|
|
|
|
|
|
|
|
|
|
Operating
expenses:
|
|
|
|
|
|
|
|
Research
and development
|
|
$
|
5,927
|
|
$
|
2,655
|
|
Sales and
marketing
|
|
|
9,535
|
|
|
7,132
|
|
General
and administrative
|
|
|
4,395
|
|
|
5,621
|
|
|
|
|
|
|
|
|
|
Total operating
expenses
|
|
|
19,857
|
|
|
15,408
|
|
|
|
|
|
|
|
|
|
Operating
loss
|
|
|
15,872
|
|
|
14,327
|
|
|
|
|
|
|
|
|
|
Total financial
expenses, net
|
|
|
44
|
|
|
639
|
|
|
|
|
|
|
|
|
|
Net
loss
|
|
$
|
15,916
|
|
$
|
14,966
|
|
|
|
|
|
|
|
|
|
Deemed
dividend
|
|
$
|
451
|
|
$
|
544
|
|
|
|
|
|
|
|
|
|
Net loss
attributable to holders of common stock
|
|
$
|
16,367
|
|
$
|
15,510
|
|
|
|
|
|
|
|
|
|
Net loss per
share:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic and
diluted loss per share
|
|
$
|
0.74
|
|
$
|
0.92
|
|
Weighted average
number of common stock used in computing basic
and diluted net loss per share
|
|
|
19,624,079
|
|
|
14,025,921
|
|
DARIOHEALTH CORP.
AND ITS SUBSIDIARIES
|
INTERIM CONSOLIDATED
STATEMENTS OF CASH FLOWS
|
U.S. dollars in
thousands
|
|
|
|
Three months
ended
|
|
|
|
March 31,
|
|
|
|
2022
|
|
2021
|
|
|
|
Unaudited
|
|
Cash flows from
operating activities:
|
|
|
|
|
|
|
|
Net loss
|
|
$
|
(15,916)
|
|
$
|
(14,966)
|
|
Adjustments
required to reconcile net loss to net cash used in operating
activities:
|
|
|
|
|
|
|
|
Stock-based compensation, common stock, and payment in stock to
directors,
employees,consultants, and service
providers
|
|
|
5,343
|
|
|
4,438
|
|
Depreciation
|
|
|
70
|
|
|
64
|
|
Change in
operating lease right of use assets
|
|
|
7
|
|
|
6
|
|
Amortization of acquired inventories step-up
|
|
|
-
|
|
|
151
|
|
Amortization of acquired intangible assets
|
|
|
963
|
|
|
375
|
|
Decrease
(increase) in trade receivables
|
|
|
(3,264)
|
|
|
318
|
|
Decrease
(increase) in other accounts receivable, prepaid expense and
long-term assets
|
|
|
(1,550)
|
|
|
207
|
|
Increase
in inventories
|
|
|
(1,555)
|
|
|
(32)
|
|
Increase
in trade payables
|
|
|
(890)
|
|
|
(544)
|
|
Decrease
in other accounts payable and accrued expenses
|
|
|
(721)
|
|
|
(609)
|
|
Increase
(decrease) in deferred revenues
|
|
|
(102)
|
|
|
93
|
|
Change in
operating lease liabilities
|
|
|
(27)
|
|
|
(33)
|
|
Remeasurement of earn-out
|
|
|
(452)
|
|
|
-
|
|
|
|
|
|
|
|
|
|
Net cash used in
operating activities
|
|
|
(18,094)
|
|
|
(10,532)
|
|
|
|
|
|
|
|
|
|
Cash flows from
investing activities:
|
|
|
|
|
|
|
|
Purchase
of property and equipment
|
|
|
(66)
|
|
|
(68)
|
|
Cash paid
as part of Upright Technologies Ltd. acquisition
|
|
|
-
|
|
|
(2,472)
|
|
Intangible assets purchases incurred, Physimax Technologies
LTD.
|
|
|
(115)
|
|
|
-
|
|
|
|
|
|
|
|
|
|
Net cash used in
investing activities
|
|
|
(181)
|
|
|
(2,540)
|
|
|
|
|
|
|
|
|
|
Cash flows from
financing activities:
|
|
|
|
|
|
|
|
Proceeds
from issuance of common stock and prefunded warrants net of
issuance costs
|
|
|
38,023
|
|
|
64,877
|
|
Proceeds
from exercise of warrants
|
|
|
-
|
|
|
633
|
|
Proceeds
from exercise of options
|
|
|
-
|
|
|
201
|
|
|
|
|
|
|
|
|
|
Net cash provided by
financing activities
|
|
|
38,023
|
|
|
65,711
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Increase in cash, cash
equivalents and restricted cash and cash equivalents
|
|
|
19,748
|
|
|
52,639
|
|
Cash, cash equivalents
and restricted cash and cash equivalents at beginning of
period
|
|
|
35,948
|
|
|
28,725
|
|
|
|
|
|
|
|
|
|
Cash,
cash equivalents and restricted cash and cash equivalents at end of
period
|
|
$
|
55,696
|
|
$
|
81,364
|
|
Reconciliation of
Revenue to Billing (Non-GAAP)
|
U.S. dollars in
thousands
|
|
|
|
Three Months
Ended
March
31,
|
|
|
|
|
2022
|
|
2021
|
|
|
|
|
|
|
|
|
|
|
|
|
|
GAAP Revenue
|
|
8,059
|
|
3,595
|
|
|
|
|
Add:
|
|
|
|
|
|
|
|
|
Change in deferred
revenue
|
|
(102)
|
|
93
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Billing
(Non-GAAP)
|
|
7,957
|
|
3,688
|
|
|
|
|
Reconciliation of
Operating Loss, Net Loss and Operating Expenses to
Adjusted
|
Operating Loss, Net
Loss and Operating Expenses (Non-GAAP)
|
U.S. dollars in
thousands
|
|
Three months ended
March 31, 2022
|
|
|
GAAP
|
Stock-Based
Compensation
Expenses
|
Earn-out
revaluation,
acquisition costs,
amortization of
acquisition
related expenses
and depreciation
of fixed assets
|
Non-GAAP
|
Cost of
Revenues
|
$
|
4,074
|
|
(23)
|
|
(954)
|
|
3,097
|
Gross Profit
|
|
3,985
|
|
23
|
|
954
|
|
4,962
|
|
|
|
|
|
|
|
|
|
Research and
development
|
|
5,927
|
|
(1,488)
|
|
(11)
|
|
4,428
|
Sales and
Marketing
|
|
9,535
|
|
(1,651)
|
|
(41)
|
|
7,843
|
General and
Administrative
|
|
4,395
|
|
(2,181)
|
|
338
|
|
2,552
|
Total Operating
Expenses
|
|
19,857
|
|
(5,320)
|
|
286
|
|
14,823
|
Operating
Loss
|
$
|
(15,872)
|
|
5,343
|
|
668
|
|
(9,861)
|
Financing
income
|
|
44
|
|
-
|
|
-
|
|
44
|
Income Tax
|
|
-
|
|
|
|
|
|
-
|
Net Loss
|
$
|
(15,916)
|
|
5,343
|
|
668
|
|
(9,905)
|
Three months ended
March 31, 2021
|
|
|
GAAP
|
Stock-Based
Compensation
Expenses
|
Amortization of
acquisition
Related expenses and
depreciation of
Fixed Assets
|
Non-GAAP
|
Cost of
Revenues
|
$
|
2,514
|
|
(13)
|
|
(557)
|
|
1,944
|
Gross Profit
|
|
1,081
|
|
13
|
|
557
|
|
1,651
|
|
|
|
|
|
|
|
|
|
Research and
development
|
|
2,655
|
|
(414)
|
|
(15)
|
|
2,226
|
Sales and
Marketing
|
|
7,132
|
|
(1,035)
|
|
(11)
|
|
6,086
|
General and
Administrative
|
|
5,621
|
|
(2,976)
|
|
(385)
|
|
2,260
|
Total Operating
Expenses
|
|
15,408
|
|
(4,425)
|
|
(411)
|
|
10,572
|
Operating
Loss
|
$
|
(14,327)
|
|
4,438
|
|
968
|
|
(8,921)
|
Financing
income
|
|
639
|
|
-
|
|
-
|
|
639
|
Net Loss
|
$
|
(14,966)
|
|
4,438
|
|
968
|
|
(9,560)
|
DarioHealth Corporate Contact
Suzanne Bedell
VP Marketing
suzanne@dariohealth.com
+1-347-767-4220
Media Contact:
Josephine
Galatioto
Josephine.Galatioto@russopartnersllc.com
+1-212-845-4262
View original
content:https://www.prnewswire.com/news-releases/dariohealth-reports-record-quarterly-revenues-in-its-2022-first-quarter-301545831.html
SOURCE DarioHealth Corp.